Detail akcie Rigel Pharm Rg online

Business Summary: Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Rigel Pharmaceuticals Inc revenues increased 10% to $58.8M. Net income decreased 24% to $8.7M. Revenues reflect Contract revenues from collaborations increase of 26% to $54.9M. Net income was offset by Biotechnology Revenues segment income decrease of 7% to $11.9M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.64 to $0.47.